Comparison of Three Eradication Treatment Protocols for Pseudomonas
                    Aeruginosa in Children and Adolescents with Cystic Fibrosis

Katharina Schütz; Simon Grewendorf; Julia Kontsendorn; Jan Fuge; Christine Happle; Isa Rudolf; Christian Dopfer; Ludwig Sedlacek; Gesine Hansen; Sibylle Junge; Anna-Maria Dittrich

doi:10.1055/a-1996-0074

Klin Padiatr 2023; 235(02): 75-83
DOI: 10.1055/a-1996-0074

Original Article

Comparison of Three Eradication Treatment Protocols for Pseudomonas Aeruginosa in Children and Adolescents with Cystic Fibrosis

Vergleich von drei Behandlungsprotokollen zur Eradikation von Pseudomonas aeruginosa bei Kindern und Jugendlichen mit Zystischer Fibrose

Authors

Katharina Schütz^*

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany

²Excellence Cluster RESIST – Resolving Infection Susceptibility, Hannover Medical School, Hannover, Germany
Simon Grewendorf^*

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany
Julia Kontsendorn

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany

³German Center for Lung Research, BREATH location, Hannover Medical School, Hannover, Germany
Jan Fuge

³German Center for Lung Research, BREATH location, Hannover Medical School, Hannover, Germany
Christine Happle

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany

²Excellence Cluster RESIST – Resolving Infection Susceptibility, Hannover Medical School, Hannover, Germany

³German Center for Lung Research, BREATH location, Hannover Medical School, Hannover, Germany
Isa Rudolf

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany

³German Center for Lung Research, BREATH location, Hannover Medical School, Hannover, Germany
Christian Dopfer

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany
Ludwig Sedlacek

⁴Institute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany
Gesine Hansen

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany

²Excellence Cluster RESIST – Resolving Infection Susceptibility, Hannover Medical School, Hannover, Germany

³German Center for Lung Research, BREATH location, Hannover Medical School, Hannover, Germany
Sibylle Junge

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany
Anna-Maria Dittrich

¹Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany

³German Center for Lung Research, BREATH location, Hannover Medical School, Hannover, Germany

Abstract

Background Pseudomonas aeruginosa (Pa) continues to affect disease progression in cystic fibrosis (CF). However, the best eradication regimen remains unclear. This work compares three different antibiotic eradication regimens in pediatric CF: an administration according to a standard-operating procedure (SOP) order vs. administration outside of this order (ooSOP).

Methods This observational study includes all CF patients<18 years who received one of three Pa eradication treatments in the past eight years at our center: 1) inhaled high-dose tobramycin (Hi-TOBI), 2) inhaled colistin+oral ciprofloxacin (COL/Cip), 3) inhaled low-dose tobramycin+4 intravenous 14-day Pa active antibiotic treatments (lo-Tobra/IV). We compared eradication rates of the three treatment regimens performed according to the SOP-based order vs. ooSOP. Logistic regression analysis was performed to identify risk factors for eradication failure.

Results Performed according to SOP order, Hi-TOBI showed the greatest efficacy, followed by lo-Tobra/IV and finally COL/Cip, while ooSOP lo-Tobra/IV was most successful, followed by COL/Cip and Hi-TOBI. Previous Pa-infections and Pa-therapies along with age at CF diagnosis were risk factors for eradication failure.

Conclusion Antibiotic treatment in SOP-based pre-defined order leads to significantly better eradication rates than individual modifications of the order of administration. A short course of inhalational high-dose Tobramycin is most successful at the first attempt. Prolonged antibiotic therapy seems to improve eradication after failed initial attempts.

Zusammenfassung

Hintergrund Pseudomonas aeruginosa (Pa) beeinträchtigt den Krankheitsverlauf bei zystischer Fibrose (CF). Das beste Eradikationsschema ist unklar. Wir vergleichen drei Antibiotika-Eradikationsschemata bei Kindern und Jugendlichen mit CF: Die Gabe nach einer Standard-Operating-Prozedur (SOP)-Reihenfolge gegenüber der nicht standardisierten Reihenfolge (ooSOP).

Methoden Diese Beobachtungsstudie umfasst alle CF-Patienten<18 Jahre, die in den letzten acht Jahren eine der drei Pa-Eradikationsbehandlungen in unserem Zentrum erhielten: 1) inhaliertes hochdosiertes Tobramycin (Hi-TOBI), 2) inhaliertes Colistin+orales Ciprofloxacin (COL/Cip), 3) inhaliertes niedrigdosiertes Tobramycin+4 intravenöse 14-tägige aktive Pa-Antibiotikabehandlungen (lo-Tobra/IV). Eradikationsraten gemäß der SOP-basierten Anordnung vs. ooSOP wurden verglichen sowie logistische Regressionsanalysen durchgeführt, um Risikofaktoren für ein Eradikationsversagen zu ermitteln.

Ergebnisse Bei Durchführung nach SOP-Reihenfolge zeigte Hi-TOBI die größte Wirksamkeit, gefolgt von lo-Tobra/IV und schließlich COL/Cip, während ooSOP lo-Tobra/IV am erfolgreichsten war, gefolgt von COL/Cip und Hi-TOBI. Frühere Pa-Infektionen und Therapien sowie Alter bei der CF-Diagnose sind Risikofaktoren für ein Scheitern der Eradikation.

Schlussfolgerung Eine Antibiotikabehandlung in einer SOP-basierten, vordefinierten Reihenfolge führt zu signifikant besseren Eradikationsraten als individuelle Modifikationen der Verabreichungsreihenfolge. Eine kurze inhalative Behandlung mit hochdosiertem Tobramycin ist beim ersten Pa-Eradikationsversuch am erfolgreichsten. Eine längere Antibiotikatherapie scheint die Eradikation nach fehlgeschlagenen ersten Versuchen zu verbessern.

Key words

Pseudomonas aeruginosa - eradication treatment protocol - Cystic fibrosis - pediatrics

Schlüsselwörter

Pseudomonas aeruginosa - Eradikationsschema - Zystische Fibrose - Pädiatriepublished online 2023

Full Text

References

References
1 Kerem E, Viviani L, Zolin A. et al. Factors associated with FEV1 decline in cystic fibrosis: Analysis of the ECFS patient registry. Eur Respir J 2014; 43: 125-133
2 McColley SA, Schechter MS, Morgan WJ. et al. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol 2017; 52: 909-915
3 Mayer-Hamblett N, Kronmal RA, Gibson RL. et al. EPIC Investigators. Initial pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012; 47: 125-134
4 Nährlich L. (ed.), Burkhart M., Wosniok J. Annual data report 2019. German Cystic Fibrosis Registry 2019
5 Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-984
6 Proesmans M, Vermeulen F, Boulanger L. et al. Comparison of two treatment regimens for eradication of pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013; 12: 29-34
7 Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N. et al. Comparative efficacy and safety of 4 randomized regimens to treat early pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165: 847-856
8 Taccetti G, Bianchini E, Cariani L. et al. Italian Group for P aeruginosa Eradication in Cystic Fibrosis. Early antibiotic treatment for pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols. Thorax 2012; 67: 853-859
9 Treggiari MM, Rosenfeld M, Mayer-Hamblett N. et al. EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study’. Contemp Clin Trials 2009; 30: 256-268
10 Doring G, Hoiby N. Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: A european consensus. J Cyst Fibros 2004; 3: 67-91
11 Wiesemann HG, Steinkamp G, Ratjen F. et al. von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25: 88-92
12 Blanchard AC, Horton E, Stanojevic S. et al. Effectiveness of a stepwise pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros 2017; 16: 395-400
13 Stanojevic S, Waters V, Mathew JL. et al. Effectiveness of inhaled tobramycin in eradicating pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros 2014; 13: 172-178
14 Mogayzel PJ, Naureckas ET, Robinson KA. et al. Cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial pseudomonas aeruginosa infection. Annals of the American Thoracic Society. 2014
15 S3-Leitlinie „Lungenerkrankung bei Mukoviszidose“, Modul 1: Diagnostik und Therapie nach dem ersten Nachweis von Pseudomonas aeruginosa [Internet]; c2013
16 Valerius NH, Koch C, Hoiby N. Prevention of chronic pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338: 725-726
17 Tiddens HA, De Boeck K, Clancy JP. et al. , ALPINE study investigators. Open label study of inhaled aztreonam for pseudomonas eradication in children with cystic fibrosis: The ALPINE study. J Cyst Fibros 2015; 14: 111-119
18 Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2017; 4: CD004197
19 Hewer SCL, Smyth AR, Brown M. et al. TORPEDO-CF study group. Intravenous versus oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): A randomised controlled trial. Lancet Respir Med 2020; 8: 975-986
20 Ratjen F, Munck A, Kho P. et al. ELITE Study Group. Treatment of early pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial. Thorax 2010; 65: 286-291
21 Cooper BG, Stocks J, Hall GL. et al. The global lung function initiative (GLI) network: Bringing the world’s respiratory reference values together. Breathe (Sheff) 2017; 13: e56-e64
22 Kromeyer-Hauschild K. Perzentile für den Body-mass-index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschrift Kinderheilkunde 2001; 149: 807-818
23 Rosenfeld M, Emerson J, McNamara S. et al. EPIC Study Group. Risk factors for age at initial pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros 2012; 11: 446-453
24 Maselli JH, Sontag MK, Norris JM. et al. Risk factors for initial acquisition of pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 2003; 35: 257-262
25 Douglas TA, Brennan S, Gard S. et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33: 305-311
26 Hewer SCL, Smyth AR, Brown M. et al. TORPEDO-CF study group. Intravenous versus oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): A randomised controlled trial. Lancet Respir Med 2020; 8: 975-986
27 Emiralioglu N, Yalcin E, Meral A. et al. The success of the different eradication therapy regimens for pseudomonas aeruginosa in cystic fibrosis. J Clin Pharm Ther 2016; 41: 419-423
28 Vidya P, Smith L, Beaudoin T. et al. Chronic infection phenotypes of pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2016; 35: 67-74
29 Li Z, Kosorok MR, Farrell PM. et al. Longitudinal development of mucoid pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. Jama 2005; 293: 581-588